Morgan Stanley maintains DXC Technology at Equal-Weight, raises price target to $12 from $9

Morgan Stanley kept DXC Technology at Equal-Weight, raising its price target to $12 from $9, a 33.3% increase. This implies a 19.9% downside from the Oct 30 close of $14.98.

Original reporting
Published Nov 2, 2026, 5:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 5:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Morgan Stanley maintains DXC Technology at Equal-Weight, raises price target to $12 from $9 — source image
Decision brief

The 30-second read

$DXCBullishLow
01

Why it matters

A higher PT can attract incremental flows from target-following strategies, but without new DXC fundamentals it is unlikely to be a major driver of price.

02

Market read

Valuation expectations for DXC shift upward via a PT increase, with limited actionable signal because the rating remains Equal-Weight.

03

What to watch

The article does not state the thesis behind the PT change, so traders lack the specific drivers to judge durability of the target.

Relevance 4/10Novelty 4/10Timing: today, as the analyst note is newly published

Background

The piece reports an analyst action from Morgan Stanley on DXC Technology, including a higher price target.

Company-level read

Ticker impact

$DXCBullishMedium confidence
Context

Morgan Stanley maintained DXC Technology at Equal-Weight and raised its price target to $12 from $9, implying a new valuation view.

Expected impact

Likely mild upward bias as traders price in the higher target, though limited follow-through versus a fundamental catalyst.

Evidence & confidence

This is an analyst rating and price-target change, not a DXC-specific operational or financial disclosure; impact is typically incremental.

Market effects

Minimal, since it is a single-name rating update without broader sector data.

None indicated.

None indicated.

Counterpoint

Equal-Weight is unchanged, so the upgrade signal is limited; traders may discount the PT increase if they expect fundamentals to drive the stock.

Key entities

  • DXC Technology

    Subject of the analyst rating and price-target change reported in the article.

  • Morgan Stanley

    Analyst firm maintaining Equal-Weight and raising the price target.

Related articles

$DXCHighAI 8/10

What DXC Technology (DXC) Said on Its Q2 Earnings Call

DXC Technology reported Q2 earnings, with CES revenue down 3.3% YoY and GIS revenue down 10%. Insurance revenue grew 23% YoY, driven by a one-time contract. DXC reduced its fiscal 2027 outlook, expecting full-year organic revenue to decline 5% to 5.5% YoY. The company generated $91M in free cash flow, excluding a $122M tax-related payment. DXC is focusing on AI and cybersecurity growth.

$DXCHighAI 8/10

DXC Technology Co (DXC) (Q2 2027) Earnings Call Highlights: Revenue Beats Guidance

DXC Technology (DXC) reported Q2 2027 revenue beating guidance but lowered full-year revenue outlook to a 5-5.5% decline due to weak bookings and pipeline conversion. Adjusted EBIT margin fell to 6.2%, and non-GAAP EPS dropped to $0.67. The company faces deal delays and increased competition, particularly in the Americas and UKI. DXC is taking cost actions to protect margins but revenue decline may pressure future profitability.

$DXCHighAI 9/10

Why is DXC Technology stock tumbling today?

DXC Technology (DXC) stock fell 12.3% in pre-market trading after reporting mixed Q2 results. While EPS ($0.67) and revenue ($3.03B) beat estimates, the company lowered FY2027 guidance, citing weak demand and execution issues. CEO Raul Fernandez attributed some weakness to 'sales execution.' Susquehanna maintained a Neutral rating with a $12 price target. The stock traded at $13.35, nearing its 52-week low.